Bree

Aldridge

PHD

Levy CIMAR Associate Director & Combinatorial Treatment Core Director

The Tuberculosis Drug Accelerator

Dr. Aldridge leads a multidisciplinary research group coupling quantitative single-cell measurements and mathematical modeling with the goal of shortening and simplifying treatment regimens against tuberculosis, which remains a threat to global health, killing ~2 million people every year. The causative agent of tuberculosis, Mycobacterium tuberculosis, is thought to infect one third of world’s population, sickening ~10 million people a year. Despite efforts to simplify treatment strategies, tuberculosis still requires months of multi-drug therapy to cure. The Aldridge Laboratory at the Tufts University School of Medicine merges engineering and molecular approaches to develop quantitative descriptions of the determinants of mycobacterial stress tolerance and virulence.

Appointments

Professor, Department of Molecular Biology and Microbiology,

Tufts University School of Medicine

Professor, Biomedical Engineering
Tufts University School of Engineering

Specialty

Mycobacterial virulence

Drug tolerance

Computational modeling

Combination therapy

Training

\

University of Arizona

BS · Computer Engineering, Molecular & Cellular Biology
\

MIT

PhD · Biological Engineering
\

Harvard School of Public Health

Postdoctoral Training